Swiss pharma giant Novartis (NOVN: VX) has expressed its satisfaction at a decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto (sacubitril/valsartan) combination patent.
Entresto is Novartis’ blockbuster heart failure drug. Its sales topped $6 billion in 2023 and now, thanks to the court ruling, market exclusivity will be maintained for the time being.
In 2019, MSN, among other generic manufacturers, submitted an Abbreviated New Drug Application (ANDA) seeking US Food and Drug Administration (FDA) approval to market and sell a generic version of Entresto. The MSN application was approved in July of last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze